Paired Phase II Studies of Erlotinib/Bevacizumab in Advanced Bronchioloalveolar Carcinoma or in Never-Smokers with Advanced Non-Small-Cell Lung Cancer (NSCLC): SWOG S0635 and S0636 Trials

Paired phase II trials, SWOG S0635 and S0636, administered erlotinib/bevacizumab to 84 patients with advanced bromnchioloalveolar carcinoma (BAC) or 85 never-smokers with advanced lung adenocarcinoma, respectively. Efficacy, particularly the primary endpoint of OS, well exceeded prior benchmarks, and the combination demonstrated no unexpected toxicity challenges. These results suggest that the erlotinib/bevacizumab combination may confer a clinical benefit in selected patients.

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2tj097v
via IFTTT